SIGA Technologies (SIGA) said Tuesday it entered into a license agreement with Vanderbilt University for a portfolio of preclinical fully human monoclonal antibodies with potential treatments for various orthopoxviruses, including smallpox and mpox.
Financial terms weren't disclosed.
Under the agreement, SIGA said it has exercised its option to license the exclusive rights to develop, manufacture, and commercialize the mAbs globally.
Shares of SIGA were down over 2% in recent trading.
Price: 6.71, Change: -0.18, Percent Change: -2.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments